Xitra Therapeutics focuses on the discovery and development of small molecules targeting Mas and MrgD, two receptors within the beneficial arm of the Renin Angiotensin System.
These novel compounds mimic the effects of the natural peptide angiotensin-(1-7), while providing superior properties such as greater potency and oral bioavailability. Xitra’s mission is to develop transformative treatments for life-threatening pediatric diseases, including congenital muscular dystrophy and epidermolysis bullosa.
Xitra Therapeutics GmbH has been funded with 850,000 Euro by the TBI Technologie-Beratungs-Institut GmbH and the State Mecklenburg-Western Pomerania to support the Research & Development programs of the company. The Minister of Economics, Infrastructure, Tourism, and Labour, Reinhard Meyer, sent the approval letter in July 2022, and we are proud to be supported by these organizations.
Entwicklung von oral applizierbaren Ang-(1-7)-Agonisten zur Behandlung von Volkskrankheiten und seltenen Erkrankungen (TBI-V-1-440-E)
Our research laboratories are located at Campus Berlin-Buch, a renowned hub for biomedical science and biotechnology.
